Relmada Therapeutics
RLMD
50 hedge funds and large institutions have $3.18M invested in Relmada Therapeutics in 2025 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 13 reducing their positions, and 7 closing their positions.
89% more capital invested
Capital invested by funds: $1.68M → $3.18M (+$1.5M)
86% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 7
14% more funds holding
Funds holding: 44 → 50 (+6)
4.64% less ownership
Funds ownership: 20.61% → 15.98% (-4.6%)
54% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$380K |
| 2 |
Corient Private Wealth
Miami,
Florida
|
+$106K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$79.3K |
| 4 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$66.7K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$61.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$433K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$312K |
| 3 |
Two Sigma Advisers
New York
|
-$135K |
| 4 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$134K |
| 5 |
Two Sigma Investments
New York
|
-$38.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Goldman Sachs
New York
| – | -$32.6K | -120,852 | Closed |
|
52
Franklin Resources
San Mateo,
California
| – | -$11.6K | -42,797 | Closed |
|
53
SEI Investments
Oaks,
Pennsylvania
| – | -$9.78K | -36,230 | Closed |
|
|
TSS
54
Two Sigma Securities
New York
| – | -$3.78K | -14,012 | Closed |
|
|
SG
55
StoneX Group
New York
| – | -$3.57K | -13,234 | Closed |
|
|
HCP
56
Hexagon Capital Partners
Rogers,
Arkansas
| – | -$1.08K | -4,000 | Closed |
|
57
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$1 | +1 | New |
|
RLMD Hedge Fund Activity: Q2 2025 in Review
50 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2025, worth a combined $3.18M — up 89% from $1.68M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RLMD positions and 7 closed out — a net gain of 6 holders — while 6 added to existing stakes and 13 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $380K. The largest seller was Vanguard Group, cutting an estimated $433K.
- 50 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2025, up from 44 in Q1 2025.
- Funds reported $3.18M of Relmada Therapeutics stock for Q2 2025, up 89% quarter-over-quarter.
- 13 funds opened new Relmada Therapeutics positions in Q2 2025 and 7 closed out, a net change of +6 holders.
- The largest Relmada Therapeutics buyer in Q2 2025 was Driehaus Capital Management, an estimated $380K added.
- The largest Relmada Therapeutics seller in Q2 2025 was Vanguard Group, an estimated $433K sold.
Based on aggregated 13F filings for Q2 2025.